Diabetes & CV Disease

Sort by:
Relevance Thumbs Up Comments Views Newest Oldest
09:26

Emory Diabetes Education Training Academy

SGLT2-i Impact on Renal or HF Outcomes: What Is Observed in Non-Diabetic Patients?

FEATURING Francisco Pasquel
  • 264 views
  • April 26, 2021
06:55

Emory Diabetes Education Training Academy

Automated Insulin Delivery: How Can Continuous Glucose Monitoring and Insulin Pump Therapy Be Integrated? What Are the Advantages and Disadvantages?

FEATURING Georgia Davis
  • 106 views
  • April 26, 2021
07:31

Emory Diabetes Education Training Academy

Remote Diabetes Management: How Has COVID-19 Advanced This Aspect Of Patient Care?

FEATURING Georgia Davis
  • 166 views
  • April 26, 2021
  • 1
23:21

The Texas Heart Institute

Diabetes Management for the Cardiac Patient: How to Utilize Latest Guidelines and Clinical Data Based on the CV Safety and Efficacy Profile of the Agents, and Individual Patient CV and Comorbidities?

FEATURING David Aguilar
  • 69 views
  • April 20, 2021
40:56

Heart Failure 2021: An Update on Therapy

Use of Dapagliflozin In Patients With HFrEF: What Are the Results Of the Landmark DAPA-HF Clinical Trial?

FEATURING Tania Gregorian
  • 54 views
  • April 20, 2021
10:53

4th Annual Cardiovascular Conference: Advances in Cardiovascular Disease - from Prevention to Intervention

SGLT2 Antagonists: How Has Their Role Expanded?

FEATURING Eugenia Gianos
  • 1,186 views
  • April 20, 2021
  • 13
13:28

4th Annual Cardiovascular Conference: Advances in Cardiovascular Disease - from Prevention to Intervention

GLP-1 Agonists: A Review of Within Class Differences for CVD Risk Reduction

FEATURING Alyson Myers
  • 1,113 views
  • April 20, 2021
  • 4
10:59

4th Annual Cardiovascular Conference: Advances in Cardiovascular Disease - from Prevention to Intervention

SGLT2 Inhibitors and GLP-1RA: How a Multidisciplinary Effort Can Be Used to Reduce Cardiovascular Risk Among High-Risk Diabetic Patients?

FEATURING Benjamin Hirsh
  • 24 views
  • April 20, 2021
11:31

Domenica Rubino

Weight Loss Maintenance for Adults With Once-Weekly Semaglutide: What Was the Observed Weight Loss Amongst Participants?

  • 1,690 views
  • April 16, 2021
  • 15
15:33

Ken Fujioka

Could GLP-1's be a 'Game Changer' For Weight Loss? Can it be a Safer Option Compared to Existing Weight Loss Drugs?

  • 8,008 views
  • April 13, 2021
  • 59
83:52

Philips

Step Ahead - Beyond the Intervention leading limb salvage outcomes

FEATURING Fadi Saab, Joseph Griffin, Jason Mendivil
  • 157 views
  • April 8, 2021
12:23

American Heart & Vascular Institute

SGLT2 Inhibitors for HF: Is this Therapy Helpful for Reducing the Hospitalization and Mortality Rate? When Should you Initiate it?

FEATURING Mary Tipton
  • 866 views
  • April 8, 2021
  • 12
26:57

Prof. Didac Mauricio

EASD/ADA Consensus Report On Management Of Hyperglycemia in T2D: Are GLP-1s The Preferred First Injectable?

  • 158 views
  • April 6, 2021
67:29

Philips

Step Ahead - PAD & CLI State of the Art and the COVID 19 Era Impacts on patient management and quality of life

FEATURING Craig Walker, Chris Lesar, Sreekumar Madassery, Timothy Yates
  • 133 views
  • April 6, 2021
06:11

Esmond Wong

Hypoglycemia Classification and Symptoms: What Happens to the Patient During a Hypoglycemic Event? Why Is It So Important to Recognize the Symptoms?

  • 51 views
  • March 31, 2021
21:04

Heart Failure 2021: An Update on Therapy

Intersection of Race and Heart Failure: How to Reduce Disparities?

FEATURING Ileana Pina
  • 19 views
  • March 31, 2021
35:56

ASPC 2020 Virtual Summit on CVD Prevention

Integrating Imaging & Advanced Blood Testing for CVD Prevention/Management: How Do We Know If the Patient Is in Prediabetes Phase? Why Do Lipoproteins Become Atherogenic? What Is the Role of Non-Lifestyle Genetic Markers?

FEATURING Arthur Agatston
  • 483 views
  • March 24, 2021
  • 3
21:16

ASPC 2020 Virtual Summit on CVD Prevention

ASPC Expert Discussion on Biologics Usage for CV Risk Reduction, Efficacy of Polypharmacy, Statin Usage in Elderly, Ischemia Trial, BP Intensity Control, and Optimal Medical Therapy Approach

FEATURING Christie Ballantyne, Ann Marie Navar, David Maron, Keith Ferdinand, Paul Ridker
  • 37 views
  • March 17, 2021
07:35

ASPC 2020 Virtual Summit on CVD Prevention

Continuity of Care for Patients With/At High Risk for CVD During COVID-19 Pandemic: How Can We Improve SoC? What Are the ASPC Recommendations?

FEATURING Amit Khera
  • 89 views
  • March 17, 2021
  • 1
28:23

ASPC 2020 Virtual Summit on CVD Prevention

New Insights Into Assessing Risk for Hispanic Patients: Why it Is Important to Discuss Risk Factors in Hispanics?

FEATURING Ileana Pina
  • 11 views
  • March 12, 2021
16:05

ASPC 2020 Virtual Summit on CVD Prevention

Polypill for CVD Prevention: When Is Polypharmacy Appropriate? Can Rosuvastatin + Candesartan + HCTZ Reduce CV Events?

FEATURING Keith Ferdinand
  • 164 views
  • March 12, 2021
  • 1
28:02

ASPC 2020 Virtual Summit on CVD Prevention

CVD Prevention for Women: What Are the Unique/Predominant Risk Factors in Women? Can Gender-Specific Management Improve ASCVD Outcomes?

FEATURING Nanette Wenger
  • 17 views
  • March 12, 2021
24:39

Philip D. Home

Ultra-Rapid Insulin in Diabetes Care: How Can More Rapidly Absorbed Insulin Help Manage HbA1c and Reduce Post-Meal Spikes?

  • 890 views
  • March 9, 2021
  • 7
19:52

Scripps Health

56 y/o Female with a History of Hepatitis C, Cirrhosis, Exertional Dyspnea and PAH: Clinical Examination and Treatment Considerations

FEATURING Rajeev Mohan, Ajay Srivastava, Thomas Heywood
  • 90 views
  • March 5, 2021
  • 1
11:36

Laura Nally

Ultra Rapid Acting Lispro: Review of the Literature and Prescribing Considerations

  • 1,396 views
  • March 1, 2021
  • 3

Diabetes & CV Disease

All Topics: